The Supreme Court Ruling in Sandoz v Amgen: A Victory for Follow-on Biologics

Ameet Sarpatwari¹, Abbe R Gluck², Gregory D Curfman^{2

3

4}

Affiliations

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Solomon Center for Health Law and Policy, Yale Law School, New Haven, Connecticut.
³ Harvard Health Publishing, Harvard Medical School, Boston, Massachusetts.
⁴ Health Care Policy and Law Editor.

Review

Ameet Sarpatwari et al. JAMA Intern Med. 2018.

. 2018 Jan 1;178(1):5-6.

doi: 10.1001/jamainternmed.2017.6145.

Ameet Sarpatwari¹, Abbe R Gluck², Gregory D Curfman^{2

3

4}

¹ Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Solomon Center for Health Law and Policy, Yale Law School, New Haven, Connecticut.
³ Harvard Health Publishing, Harvard Medical School, Boston, Massachusetts.
⁴ Health Care Policy and Law Editor.

Erratum in

Imprecise Percentages.
[No authors listed] [No authors listed] JAMA Intern Med. 2018 Jan 1;178(1):157. doi: 10.1001/jamainternmed.2017.7836. JAMA Intern Med. 2018. PMID: 29336536 Free PMC article. No abstract available.

No abstract available